Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events-Reference-Cited by-同舟云学术

Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events

Published:2022 Issue:3 Volume:62 Page:154-157
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Ishitsuka Kantaro¹,Yokoyama Yasuhisa¹,Baba Naoko¹,Matsuoka Ryota²,Sakamoto Noriaki²,Sakamoto Tatsuhiro¹,Kusakabe Manabu¹,Kato Takayasu³,Kurita Naoki¹,Nishikii Hidekazu¹,Sakata-Yanagimoto Mamiko¹,Obara Naoshi¹,Hasegawa Yuichi¹,Chiba Shigeru¹

Affiliation:

1. Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan,

2. Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

3. Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan,

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/62/3/62_21035/_pdf

Reference8 articles.

1. 1 Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin’s lymphoma. Hepatology. 1993; 17: 70-77.